Clinical evidence
Improved survival rate
The first version of the ARNE device was used for a study, based on the results of this first study, we can say with certainty that the error rate and the number of missed steps decreases performing newborn life support. Resuscitation will also be faster, and the correct steps will be taken in good time. The assumption is therefore that survival will improve and very importantly, that the quality of survival will also be higher. Especially the babies who survive with many residual symptoms are very expensive for the community for the rest of their lives.
More information can be read here.
NLS Guideline adherence needs improvement
The European resuscitation council (ERC) and the American Heart Association (AHA) provides standardized guidelines for neonatal resuscitation and facilitation of transition after birth. The question is, how well do delivery room teams adhere to these guidelines? Clearly there is a need for improvement.
ARNE addresses this need, providing the first ever clinical decision support device for Newborn life support procedures.
More information can be read here.